Legend Biotech (NASDAQ:LEGN) Stock Price Target Lowered at Barclays

Posted by George Bondi on Oct 13th, 2026

Legend Biotech (NASDAQ:LEGN – Get Free Report) had its target price cut by stock analysts at Barclays from $74.00 to $68.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 283.21% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the stock. Royal Bank Of Canada lowered their target price on shares of Legend Biotech from $58.00 to $56.00 and set an “outperform” rating on the stock in a report on Thursday, October 8th. Morgan Stanley set a $65.00 price objective on shares of Legend Biotech in a research note on Friday, September 4th. JPMorgan Chase & Co. cut their target price on shares of Legend Biotech from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Friday. UBS Group reiterated a “buy” rating and issued a $65.00 target price on shares of Legend Biotech in a research note on Monday, September 28th. Finally, TD Cowen reduced their price target on Legend Biotech from $29.00 to $24.00 and set a “hold” rating for the company in a report on Wednesday, August 12th. Nine analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Legend Biotech currently has an average rating of “Moderate Buy” and an average target price of $55.07.

Get Our Latest Report on Legend Biotech

Legend Biotech Stock Performance

LEGN traded down $0.06 on Tuesday, hitting $17.75. 991,564 shares of the company were exchanged, compared to its average volume of 2,416,353. Legend Biotech has a 12 month low of $16.24 and a 12 month high of $37.50. The company has a market cap of $3.44 billion, a PE ratio of -70.96 and a beta of 0.57. The stock’s fifty day moving average is $19.79 and its 200-day moving average is $23.61.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. Legend Biotech had a negative return on equity of 8.71% and a negative net margin of 7.21%. The firm had revenue of $387.50 million during the quarter, compared to the consensus estimate of $355.96 million. During the same period last year, the company earned $0.03 earnings per share. The business’s revenue was up 51.9% compared to the same quarter last year. As a group, equities research analysts expect that Legend Biotech will post -0.09 EPS for the current fiscal year.

Insider Activity

In other Legend Biotech news, CFO Carlos Santos sold 5,430 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $9.14, for a total transaction of $49,630.20. Following the completion of the sale, the chief financial officer directly owned 14,246 shares in the company, valued at $130,208.44. This trade represents a 27.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $9.46, for a total value of $258,920.20. Following the transaction, the director owned 52,731 shares in the company, valued at approximately $498,835.26. This trade represents a 34.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.02% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. bought a new stake in shares of Legend Biotech in the second quarter valued at about $55,307,000. Squarepoint Ops LLC increased its position in Legend Biotech by 60.4% during the second quarter. Squarepoint Ops LLC now owns 769,252 shares of the company’s stock worth $22,216,000 after acquiring an additional 289,772 shares during the period. SG Americas Securities LLC increased its position in Legend Biotech by 44.1% during the first quarter. SG Americas Securities LLC now owns 535,658 shares of the company’s stock worth $9,690,000 after acquiring an additional 163,930 shares during the period. Renaissance Technologies LLC raised its stake in Legend Biotech by 29.5% in the 1st quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock worth $9,439,000 after purchasing an additional 119,000 shares in the last quarter. Finally, Candriam S.C.A. raised its stake in Legend Biotech by 79.6% in the 1st quarter. Candriam S.C.A. now owns 470,292 shares of the company’s stock worth $8,508,000 after purchasing an additional 208,477 shares in the last quarter. Institutional investors own 70.89% of the company’s stock.

About Legend Biotech

(Get Free Report)

Legend Biotech Corporation (NASDAQ: LEGN) is a biotechnology company focused on developing, manufacturing and commercializing cell therapies for cancer and other serious diseases. Its research centers on chimeric antigen receptor T-cell (CAR-T) therapies, which use genetically modified immune cells to recognize and attack cancer cells.

The company’s leading product is Carvykti (ciltacabtagene autoleucel), a B-cell maturation antigen (BCMA)-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma.